medac
As of the edition of 20 October 2026, medac runs 3 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methotrexate | none listed | 2 |
| Treosulfan | Ends 2032 (exclusivity) | 0 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 6 trials led
- Cancer: 5 trials led
- Inherited and neonatal: 1 trials led